PREVALENCE OF DRUG RESISTANCE TO FIRST LINE DRUGS AMONG TUBERCULOSIS PATIENTS IN ASTANA
https://doi.org/10.21292/2075-1230-2018-96-8-50-54
Abstract
The objective of the study: to study the prevalence of resistance to first line drugs among tuberculosis patients in Astana (Kazakhstan Republic).
Subjects and methods. Data on resistance to first line drugs according to the WHO classification were analyzed, they included sputum test results of 449 patients with bacillary excretion who received in-patient treatment in TB Dispensary in Astana in 2017. Bactec and Hain test were used for drug susceptibility testing.
Results. The study showed that among new tuberculosis patients and relapses, resistance to isoniazid (H) dominated and made 87.4% (76 out of 87) and 91.1% (41 out of 45) of cases respectively. Resistance to H was registered more often versus resistance to streptomycin. H-resistant strains were detected confidently more often than rifampicin resistance: 76/226 (33.6%) versus 18/226 (8.0%) among all new cases (p < 0.01) and 41/133 (26.1%) versus 5/133 (3.2%) of all relapses (p < 0.01).
Among new cases with drug resistant tuberculosis, the frequency of rifampicin resistant strains was compatible with the frequency of resistance to ethambutol. It was found out that the frequency of resistance to pyrazinamide was low.
The performed analysis confirmed that when prescribing treatment to tuberculosis patients it was necessary to investigate the resistance to first line drugs with much detail.
About the Authors
Z. K. Rakisheva
TB Dispensary of Astana.
Kazakhstan
Kazakhstan
Zhanna K. Rakisheva.
14, Manasa St., Astana, Almaty District, Z01A4M6.
G. S. Balasanyants
S.M. Kirov Military Medical Academy.
Russian Federation
Russian Federation
Goar S. Balasanyants , Doctor of Medical Sciences, Professor, Associate Professor of Phthisiology Department.
93, Toreza Ave., St. Petersburg, 194214
A. S. Akisheva
TB Dispensary of Astana.
Russian Federation
Russian Federation
Akmaral S. Akisheva Head of Clinical Bacteriological Laboratory.
14, Manasa St., Astana, Almaty District, Z01A4M6.
A. B. Tsepke
TB Dispensary of Astana.
Russian Federation
Russian Federation
Anna B. Tsepke Chief Doctor.
14, Manasa St., Astana, Almaty District, Z01A4M6.
N. S. Solovieva
St. Petersburg Phthisiopulmonology Research Institute.
Russian Federation
Russian Federation
Natalya S. Solovieva Head of Bacteriological Laboratory.
2-4, Ligovsky Ave., St. Petersburg, 191036
References
1. Al-Mutairi N.M., Ahmad S., Mokaddas E. Molecular screening versus phenotypic susceptibility testing of multidrug-resistant mycobacterium tuberculosis Isolates for streptomycin and ethambutol. Microb. Drug. Resist., 2018, Jan. 16. https://doi.org/10.1089/mdr.2017.0294
2. Asaad A.M., Alqahtani J.M. Primary anti-tuberculous drugs resistance of pulmonary tuberculosis in southwestern Saudi Arabia. J. Infect. Public Health, 2012, vol. 5, no. 4, pp. 281-285.
3. Cambau E., Viveiros M., Machado D., Raskine L., Ritter C., Tortoli E., Matthys V., Hoffner S., Richter E., Del Molino M.P., Cirillo D.M. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J. Antimicrob. Chemother., 2015, vol. 70, no. 3, pp. 686-696.
4. Kim H.W., Kim J.S. Treatment of latent tuberculosis infection and its clinical efficacy. Tuberc. Respir. Dis. (Seoul), 2018, vol. 81, no. 1, pp. 6-12.
5. Kuo C.Y., Wang W.H., Huang C.H., Chen Y.H., Lu P.L. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment. J. Microbiol. Immunol. Infect., 2017, vol. 17, pp. S1684-S1182.
6. Meyssonnier V., van Bu Th., Veziris N. et al. Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis. DVC Infect. Dis., 2014, vol. 14, pp. 18.
7. Migliori G.B., Zellweger J.P., Abubakar I. et al. European Union standards for tuberculosis care. Eur Respir J., 2012, vol. 39, no. 4, pp. 807-819.
8. National Institute for Health and Clinical Excellence (NICE) Tuberculosis (NICE guideline 33). London, NICE, 2016
9. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, World Health Organization, 2014.
10. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis.5th ed.. Geneva, WHO, 2015.
11. World Health Organization. Treatment guidelines for drug-resistant tuberculosis. Geneva, WHO, 2016.
12. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva, WHO, 2011.
13. Zignol M., Dean A. S., Alikhanova N. et al. Population-based resistance of mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect. Dis., 2016, vol. 16, no. 10, pp. 1185-1192.
Review
For citations:
Rakisheva Z.K., Balasanyants G.S., Akisheva A.S., Tsepke A.B., Solovieva N.S. PREVALENCE OF DRUG RESISTANCE TO FIRST LINE DRUGS AMONG TUBERCULOSIS PATIENTS IN ASTANA. Tuberculosis and Lung Diseases. 2018;96(8):50-54. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-8-50-54
Views:
1033
Email this article 